[go: up one dir, main page]

PE20030443A1 - Uso de compuestos en un inhalador de polvo seco - Google Patents

Uso de compuestos en un inhalador de polvo seco

Info

Publication number
PE20030443A1
PE20030443A1 PE2002000894A PE2002000894A PE20030443A1 PE 20030443 A1 PE20030443 A1 PE 20030443A1 PE 2002000894 A PE2002000894 A PE 2002000894A PE 2002000894 A PE2002000894 A PE 2002000894A PE 20030443 A1 PE20030443 A1 PE 20030443A1
Authority
PE
Peru
Prior art keywords
alkyl
cyclopentil
alcoxy
triazolo
dihydro
Prior art date
Application number
PE2002000894A
Other languages
English (en)
Inventor
Michael John Humphrey
Paul Robert Miller
Michael Trevor Shepherd
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030443A1 publication Critical patent/PE20030443A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE INHALACION QUE COMPRENDE UN COMPUESTO DE FORMULA I R1 ES H, ALQUILO (C1-C6), ALCOXI (C1-C6), ALQUENILO (C2-C4), ENTRE OTROS; R2 Y R3 SON H, ALQUILO (C1-C14), ALCOXI (C1-C7)-ALQUILO (C1-C7), ALQUENILO (C2-C14), ENTRE OTROS; R9 Y R10 SON H, ALQUILO (C1-C6), ALCOXI (C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS 9-CICLOPENTIL-5,6-DIHIDRO-7-ETIL-3-FENIL-9H-PIRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-O]PIRIDINA, 9-CICLOPENTIL-5,6-DIHIDRO-7-ETIL-3-(FURAN-2-IL)-9H-PIRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-O]PIRIDINA, 3-(TERC-BUTIL)-9-CICLOPENTIL-5,6-DIHIDRO-7-ETIL-3-(TIEN-2-IL)-9H-PIRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-O] PIRIDINA, ENTRE OTROS. LA FORMULACION SE CARACTERIZA PORQUE LAS PARTICULAS DE FARMACO SOLIDAS FINAS TIENEN UNA DISTRIBUCION DE TAMANOS TAL QUE EL 90% DE LAS PARTICULAS TIENE UN DIAMETRO MENOR DE 10 MICROMETROS Y EL 50% TIENEN UN DIAMETRO MENOR DE 5 MICROMETROS Y SE SUMINISTRAN POR MEDIO DE UN INHALADOR DE DOSIS. LAS MICROESFERAS COMPRENDEN POLI(ACIDO D,L-LACTICO-CO-GLICOLICO). LA FORMULACION DE INHIBE LA PDE4 Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
PE2002000894A 2001-09-12 2002-09-10 Uso de compuestos en un inhalador de polvo seco PE20030443A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0122031.8A GB0122031D0 (en) 2001-09-12 2001-09-12 Use of pde4 inhibitors in a dry powder inhaler

Publications (1)

Publication Number Publication Date
PE20030443A1 true PE20030443A1 (es) 2003-05-17

Family

ID=9921954

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2002000893A PE20030509A1 (es) 2001-09-12 2002-09-10 Uso de una combinacion de compuestos en un inhalador de polvo seco
PE2002000894A PE20030443A1 (es) 2001-09-12 2002-09-10 Uso de compuestos en un inhalador de polvo seco

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2002000893A PE20030509A1 (es) 2001-09-12 2002-09-10 Uso de una combinacion de compuestos en un inhalador de polvo seco

Country Status (34)

Country Link
US (3) US20030064031A1 (es)
EP (1) EP1427414A1 (es)
JP (1) JP2005505560A (es)
KR (1) KR20040036940A (es)
CN (1) CN1553801A (es)
AP (2) AP2002002623A0 (es)
AR (2) AR036473A1 (es)
BG (1) BG108569A (es)
BR (1) BR0212449A (es)
CA (1) CA2457717A1 (es)
CZ (1) CZ2004310A3 (es)
EA (1) EA006742B1 (es)
EC (1) ECSP045018A (es)
EE (1) EE200400078A (es)
GB (1) GB0122031D0 (es)
HN (2) HN2002000253A (es)
HR (1) HRP20040162A2 (es)
HU (1) HUP0401890A3 (es)
IL (1) IL160380A0 (es)
IS (1) IS7151A (es)
MA (1) MA27062A1 (es)
MX (1) MXPA04002354A (es)
NO (1) NO20041011L (es)
NZ (1) NZ530929A (es)
OA (1) OA12660A (es)
PA (2) PA8554701A1 (es)
PE (2) PE20030509A1 (es)
PL (1) PL368736A1 (es)
SK (1) SK1272004A3 (es)
SV (2) SV2004001227A (es)
TN (1) TNSN04040A1 (es)
TW (1) TW200602054A (es)
WO (2) WO2003022279A1 (es)
ZA (1) ZA200401002B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
KR20050088242A (ko) * 2002-12-31 2005-09-02 넥타르 테라퓨틱스 진균 감염 요법을 위한 에어로졸화가능한 약제학적 제형물
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
EP1931338A4 (en) * 2005-09-28 2009-05-27 Merck Frosst Canada Inc AEROSOL POWDER FORMULATION COMPRISING A TAMISED LACTOSE
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
KR20150076005A (ko) 2013-12-26 2015-07-06 삼성디스플레이 주식회사 액정 표시 장치
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
KR102379309B1 (ko) * 2014-09-15 2022-03-28 베로나 파마 피엘씨 Rpl554를 포함하는 액상 흡입제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172583T3 (es) * 1995-06-06 2002-10-01 Pfizer 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas.
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren

Also Published As

Publication number Publication date
WO2003022275A1 (en) 2003-03-20
OA12660A (en) 2006-06-19
SV2004001226A (es) 2004-02-24
PE20030509A1 (es) 2003-06-23
AR036473A1 (es) 2004-09-08
MXPA04002354A (es) 2004-06-29
HUP0401890A3 (en) 2008-03-28
ZA200401002B (en) 2005-02-07
NO20041011L (no) 2004-03-10
AR036474A1 (es) 2004-09-08
EP1427414A1 (en) 2004-06-16
HN2002000253A (es) 2003-04-07
TW200602054A (en) 2006-01-16
GB0122031D0 (en) 2001-10-31
IL160380A0 (en) 2004-07-25
JP2005505560A (ja) 2005-02-24
PA8554601A1 (es) 2003-09-17
NZ530929A (en) 2006-08-31
ECSP045018A (es) 2004-04-28
PL368736A1 (en) 2005-04-04
KR20040036940A (ko) 2004-05-03
US20050232871A1 (en) 2005-10-20
HRP20040162A2 (en) 2004-08-31
EA200400301A1 (ru) 2004-06-24
SV2004001227A (es) 2004-02-24
PA8554701A1 (es) 2003-09-17
BR0212449A (pt) 2004-08-17
CA2457717A1 (en) 2003-03-20
SK1272004A3 (sk) 2005-03-04
MA27062A1 (fr) 2004-12-20
AP2002002623A0 (en) 2002-09-30
EE200400078A (et) 2004-06-15
IS7151A (is) 2004-02-13
HN2002000254A (es) 2003-04-07
BG108569A (bg) 2005-02-28
US20030064034A1 (en) 2003-04-03
EA006742B1 (ru) 2006-04-28
US20030064031A1 (en) 2003-04-03
CZ2004310A3 (cs) 2005-02-16
WO2003022279A1 (en) 2003-03-20
TNSN04040A1 (fr) 2006-06-01
CN1553801A (zh) 2004-12-08
HUP0401890A2 (hu) 2004-12-28
AP2002002624A0 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
PE20030443A1 (es) Uso de compuestos en un inhalador de polvo seco
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
AR041969A1 (es) Medicamento para el tratamiento de la enfermedad pulmonar obstructiva cronica
ATE425166T1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
MY130803A (en) New quinuclidine amide derivatives
BG111017A (bg) Нови кристални и аморфна форми на съединението триазоло (4, 5- d)пиримидин
HUP9902076A2 (hu) Szexuális rendellenességek kezelésére alkalmas intranazális készítmény
HUP0303350A2 (hu) Szubsztituált imidazo[1,2-a]piridin-, imidazo[1,2-a]pirimidin- és imidazo[1,2-a] pirazin-3-il-amin származékok alkalmazása NOS-inhibitor gyógyszerkészítmények előállítására
JO2371B1 (en) 4-phenyl-pyridine derivatives
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
HUP0303480A2 (hu) 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA05012247A (es) Derivados de bencimidazol nuevos.
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
IL162614A0 (en) Liposomal delivery of vitamin e based compounds
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MX2009006454A (es) Derivados de espiro-piperidina.
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
WO2005000840A8 (en) Substituted diketopiperazines and their use as oxytocin antagonists

Legal Events

Date Code Title Description
FD Application declared void or lapsed